Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2016 (2016), Article ID 4534898, 3 pages
http://dx.doi.org/10.1155/2016/4534898
Case Report

False Positive B-Cells Crossmatch after Prior Rituximab Exposure of the Kidney Donor

Department of Histocompatibility, Amiens University Medical Center, 80000 Amiens, France

Received 2 March 2016; Accepted 13 April 2016

Academic Editor: Gerald Schlaf

Copyright © 2016 Judith Desoutter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Guillaume, H. Mazouz, V. Piot, C. Presne, and P.-F. Westeel, “Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screening,” Tissue Antigens, vol. 82, no. 1, pp. 16–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Alheim, P. K. Paul, D.-M. Hauzenberger, and A.-C. Wikström, “Improved flow cytometry based cytotoxicity and binding assay for clinical antibody HLA crossmatching,” Human Immunology, vol. 76, no. 11, pp. 849–857, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Schlaf, B. Pollok-Kopp, E. Schabel, and W. Altermann, “Artificially positive crossmatches not leading to the refusal of kidney donations due to the usage of adequate diagnostic tools,” Case Reports in Transplantation, vol. 2013, Article ID 746395, 6 pages, 2013. View at Publisher · View at Google Scholar
  4. J. Visentin, M. Vigata, S. Daburon et al., “Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays,” Transplantation, vol. 98, no. 6, pp. 625–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Milongo, G. Vieu, S. Blavy et al., “Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results,” Transplant Immunology, vol. 32, no. 3, pp. 151–155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. B. K. Book, A. Agarwal, A. B. Milgrom et al., “New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies,” Transplantation Proceedings, vol. 37, no. 2, pp. 640–642, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Bearden, A. Agarwal, B. K. Book et al., “Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab,” Human Immunology, vol. 65, no. 8, pp. 803–809, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Feugier, “A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas,” Future Oncology, vol. 11, no. 9, pp. 1327–1342, 2015. View at Publisher · View at Google Scholar · View at Scopus